Recursion Pharmaceuticals Earnings Estimate

By analyzing Recursion Pharmaceuticals' earnings estimates, investors can diagnose different trends across Recursion Pharmaceuticals' analyst sentiment over time as well as compare current EPS estimates against different timeframes. Please be aware that the consensus of earnings estimates for Recursion Pharmaceuticals is based on EPS before non-recurring items and includes expenses related to employee stock options. Recursion Pharmaceuticals is projected to generate -0.385825 in earnings per share on the 31st of December 2024. Recursion Pharmaceuticals earnings estimates module stress-tests analyst consensus about projected Recursion Pharmaceuticals EPS (Earning Per Share) to derive its highest and lowest estimates based on its historical volatility. Many public companies, such as Recursion Pharmaceuticals, manage the perception of their earnings on a regular basis to make sure that analyst estimates are accurate. Future earnings calculations are also an essential input when attempting to value a firm. By analyzing Recursion Pharmaceuticals' earnings estimates, investors can diagnose different trends across Recursion Pharmaceuticals' analyst sentiment over time as well as compare current estimates against different timeframes. At this time, Recursion Pharmaceuticals' Gross Profit is fairly stable compared to the past year. Gross Profit Margin is likely to rise to 0.05 in 2024, whereas Pretax Profit Margin is likely to drop (7.82) in 2024. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Recursion Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For more information on how to buy Recursion Stock please use our How to Invest in Recursion Pharmaceuticals guide.